Publications from OUS - Section for lung oncology

212 publications found

1. Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A (2024)
   Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study
   Acta Oncol, 63, 213-219
   DOI 10.2340/1651-226X.2024.24179, PubMed 38647024
2. Brativnyk A, Ankill J, Helland Å, Fleischer T (2024)
   Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma
   Int J Cancer (in press)
   DOI 10.1002/ijc.34915, PubMed 38489486
3. Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å (2024)
   UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
   Eur J Cancer, 202, 113973
   DOI 10.1016/j.ejca.2024.113973, PubMed 38447379
4. Nilssen Y, Brustugun OT, Fjellbirkeland L, Helland Å, Møller B, Wahl SGF, Solberg S (2024)
   Distribution and characteristics of malignant tumours by lung lobe
   BMC Pulm Med, 24 (1), 106
   DOI 10.1186/s12890-024-02918-w, PubMed 38439038
5. Gullhaug A, Haakensen VD, De Ruysscher D, Simone CB, Hotca-Cho AE, Chhabra AM, Hellebust TP, Paulsen EE, Dimopoulos MP, Johansen S (2024)
   Lung cancer reirradiation: Exploring modifications to utilization, treatment modalities and factors associated with outcomes
   J Med Imaging Radiat Sci (in press)
   DOI 10.1016/j.jmir.2024.02.004, PubMed 38429174
6. Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K (2024)
   [Not Available]
   Tidsskr Nor Laegeforen, 144 (1)
   DOI 10.4045/tidsskr.23.0740, PubMed 38258713
7. Mahon P, Chatzitheofilou I, Dekker A, Fernández X, Hall G, Helland A, Traverso A, Van Marcke C, Vehreschild J, Ciliberto G, Tonon G (2024)
   A federated learning system for precision oncology in Europe: DigiONE
   Nat Med, 30 (2), 334-337
   DOI 10.1038/s41591-023-02715-8, PubMed 38195748
8. Helland Å, Myklebust TÅ, Conte S, Frederiksen LE, Aarøe J, Enerly E (2023)
   EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study
   Cancer Treat Res Commun, 38, 100785
   DOI 10.1016/j.ctarc.2023.100785, PubMed 38190787
9. Ringborg U, von Braun J, Celis J, Baumann M, Berns A, Eggermont A, Heard E, Heitor M, Chandy M, Chen CJ, Costa A, De Lorenzo F, De Robertis EM, Dubee FC, Ernberg I, Gabriel M, Helland Å, Henrique R, Jönsson B, Kallioniemi O, Korbel J, Krause M, Lowy DR, Michielin O, Nagy P et al. (2024)
   Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023
   Mol Oncol, 18 (2), 245-279
   DOI 10.1002/1878-0261.13575, PubMed 38135904
10. Huynh TM, Dale E, Falk RS, Hellebust TP, Astrup GL, Malinen E, Edin NFJ, Bjordal K, Herlofson BB, Kiserud CE, Helland Å, Amdal CD (2023)
    Radiation-induced long-term dysphagia in survivors of head and neck cancer and association with dose-volume parameters
    Radiother Oncol, 190, 110044
    DOI 10.1016/j.radonc.2023.110044, PubMed 38061420
11. Le Tourneau C, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, Taskén K, Thomas DM, Veronese ML, Durán-Pacheco G, Leyens L, Rufibach K, Thomas M, Krämer A (2023)
    Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
    Eur J Cancer, 194, 113278
    DOI 10.1016/j.ejca.2023.113278, PubMed 37820553
12. Børø S, Thoresen S, Boge Brant S, Helland Å (2023)
    Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer
    Acta Oncol, 62 (12), 1642-1648
    DOI 10.1080/0284186X.2023.2264484, PubMed 37801361
13. Yi D, Grøvik E, Tong E, Iv M, Emblem KE, Nilsen LB, Saxhaug C, Latysheva A, Jacobsen KD, Helland Å, Zaharchuk G, Rubin D (2023)
    Erratum: "MRI pulse sequence integration for deep-learning-based brain metastases segmentation"
    Med Phys, 50 (8), 5294
    DOI 10.1002/mp.16594, PubMed 37573581
14. Langberg CW, Horndalsveen H, Helland Å, Haakensen VD (2023)
    Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
    Front Oncol, 13, 1217424
    DOI 10.3389/fonc.2023.1217424, PubMed 37476372
15. Hanekamp BA, Viktil E, Slørdahl KS, Dormagen JB, Kløw NE, Malinen E, Brunborg C, Guren MG, Schulz A (2023)
    Magnetic resonance imaging of anal cancer: tumor characteristics and early prediction of treatment outcome
    Strahlenther Onkol, 200 (1), 19-27
    DOI 10.1007/s00066-023-02114-5, PubMed 37429949
16. Lindberg S, Grozman V, Karlsson K, Onjukka E, Lindbäck E, Jirf KA, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA, Møller DS, Hoffmann L, Knap MM, Nyman J, Drugge N, Bergström P, Olofsson J, Rogg LV, Hagen RK, Frøland AS, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB et al. (2023)
    Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors
    Int J Radiat Oncol Biol Phys, 117 (5), 1222-1231
    DOI 10.1016/j.ijrobp.2023.06.246, PubMed 37423292
17. Nilssen Y, Solberg S, Brustugun OT, Møller B, Sundset A, Wahl SGF, Helland Å (2023)
    Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people
    Eur J Cardiothorac Surg, 64 (1)
    DOI 10.1093/ejcts/ezad244, PubMed 37348858
18. Ottesen JA, Yi D, Tong E, Iv M, Latysheva A, Saxhaug C, Jacobsen KD, Helland Å, Emblem KE, Rubin DL, Bjørnerud A, Zaharchuk G, Grøvik E (2023)
    2.5D and 3D segmentation of brain metastases with deep learning on multinational MRI data
    Front Neuroinform, 16, 1056068
    DOI 10.3389/fninf.2022.1056068, PubMed 36743439
19. Skoie IM, Skogås JG, Langø T, Myhr KM, Myhre PL, Goll R, Fretland SØ, Helland Å (2023)
    New centres to carry out more clinical trials in Norway
    Tidsskr Nor Laegeforen, 143 (2)
    DOI 10.4045/tidsskr.22.0722, PubMed 36718905
20. Børø S, Thoresen S, Helland Å (2022)
    Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 - 2020 - A population-based registry study from Norway
    Front Oncol, 12, 1017902
    DOI 10.3389/fonc.2022.1017902, PubMed 36523970
21. Gulati G, Tjessem KH, Horndalsveen H, Halvorsen S, Haakensen VD (2022)
    [Checkpoint inhibitor-induced myocarditis]
    Tidsskr Nor Laegeforen, 142 (18)
    DOI 10.4045/tidsskr.21.0817, PubMed 36511752
22. Maggadóttir SM, Kvalheim G, Wernhoff P, Sæbøe-Larssen S, Revheim ME, Josefsen D, Wälchli S, Helland Å, Inderberg EM (2022)
    A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
    Front Oncol, 12, 1031232
    DOI 10.3389/fonc.2022.1031232, PubMed 36439452
23. Horndalsveen H, Alver TN, Dalsgaard AM, Rogg LV, Helbekkmo N, Grønberg BH, Halvorsen TO, Ramberg C, Haakensen VD, Öjlert ÅK, Bjaanaes MM, Helland Å (2022)
    Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial
    Mol Oncol, 17 (3), 487-498
    DOI 10.1002/1878-0261.13330, PubMed 36330681
24. Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B (2022)
    Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
    J Thorac Oncol, 18 (2), 181-193
    DOI 10.1016/j.jtho.2022.10.003, PubMed 36307040
25. Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T (2022)
    Corrigendum: Circulating T cell activation and exhaustion markers are associated with radiation pneumonitis and poor survival in non-small-cell lung cancer
    Front Immunol, 13, 1051156
    DOI 10.3389/fimmu.2022.1051156, PubMed 36263024
26. Helland Å, Andersen KK, Myklebust TÅ, Johannesen TB, Aarøe J, Enerly E (2022)
    EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study
    Cancer Treat Res Commun, 33, 100636
    DOI 10.1016/j.ctarc.2022.100636, PubMed 36155129
27. Solberg S, Nilssen Y, Terje Brustugun O, Magnus Haram P, Helland Å, Møller B, Strand TE, Gyrid Freim Wahl S, Fjellbirkeland L (2022)
    Concordance between clinical and pathology TNM-staging in lung cancer
    Lung Cancer, 171, 65-69
    DOI 10.1016/j.lungcan.2022.07.014, PubMed 35926242
28. Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T (2022)
    Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer
    Front Immunol, 13, 875152
    DOI 10.3389/fimmu.2022.875152, PubMed 35911763
29. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
    Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
    J Transl Med, 20 (1), 317
    DOI 10.1186/s12967-022-03518-0, PubMed 35841045
30. Eide IJZ, Stensgaard S, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Sørensen BS, Brustugun OT (2022)
    Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
    Transl Lung Cancer Res, 11 (6), 953-963
    DOI 10.21037/tlcr-21-995, PubMed 35832438
31. Khadse A, Haakensen VD, Silwal-Pandit L, Hamfjord J, Micke P, Botling J, Brustugun OT, Lingjærde OC, Helland Å, Kure EH (2022)
    Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
    Front Oncol, 12, 873532
    DOI 10.3389/fonc.2022.873532, PubMed 35574381
32. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
    Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
    J Transl Med, 20 (1), 225
    DOI 10.1186/s12967-022-03432-5, PubMed 35568909
33. Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
    A national precision cancer medicine implementation initiative for Norway
    Nat Med, 28 (5), 885-887
    DOI 10.1038/s41591-022-01777-4, PubMed 35513529
34. Killingberg KT, Halvorsen TO, Fløtten Ø, Brustugun OT, Langer SW, Nyman J, Hornslien K, Madebo T, Schytte T, Risum S, Tsakonas G, Engleson J, Grønberg BH (2022)
    Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer
    Lung Cancer, 166, 49-57
    DOI 10.1016/j.lungcan.2022.02.002, PubMed 35183991
35. Umu SU, Langseth H, Zuber V, Helland Å, Lyle R, Rounge TB (2022)
    Serum RNAs can predict lung cancer up to 10 years prior to diagnosis
    Elife, 11
    DOI 10.7554/eLife.71035, PubMed 35147498
36. Lehtiö J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, Umer HM, Mermelekas G, Pirmoradian M, Jönsson M, Brunnström H, Brustugun OT, Purohit KP, Cunningham R, Foroughi Asl H, Isaksson S, Arbajian E, Aine M, Karlsson A, Kotevska M, Gram Hansen C, Drageset Haakensen V, Helland Å, Tamborero D, Johansson HJ et al. (2021)
    Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms
    Nat Cancer, 2 (11), 1224-1242
    DOI 10.1038/s43018-021-00259-9, PubMed 34870237
37. Frafjord A, Buer L, Hammarström C, Aamodt H, Woldbæk PR, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2021)
    The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
    Front Immunol, 12, 764596
    DOI 10.3389/fimmu.2021.764596, PubMed 34868011
38. Bjaanæs MM, Nilsen G, Halvorsen AR, Russnes HG, Solberg S, Jørgensen L, Brustugun OT, Lingjærde OC, Helland Å (2021)
    Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
    BMC Cancer, 21 (1), 1089
    DOI 10.1186/s12885-021-08811-7, PubMed 34625038
39. Eide IJZ, Brustugun OT (2021)
    [Lung cancer treated abroad with receptor tyrosine kinase inhibitor]
    Tidsskr Nor Laegeforen, 141
    DOI 10.4045/tidsskr.21.0147, PubMed 34505490
40. Thorsteinsdottir T, Brustugun OT (2021)
    [Cholangiocarcinoma treated with a tumour-agnostic drug]
    Tidsskr Nor Laegeforen, 141
    DOI 10.4045/tidsskr.21.0064, PubMed 34505477
41. Farooqi SJ, Bjaanæs MM, Helland Å, Haakensen VD (2021)
    [Immunotherapy for malignant pleural mesothelioma]
    Tidsskr Nor Laegeforen, 141
    DOI 10.4045/tidsskr.21.0503, PubMed 34505475
42. Eide IJZ, Grut H, Helland Å, Ekman S, Sørensen JB, Hansen KH, Grønberg BH, Cicenas S, Koivunen JP, Mellemgaard A, Brustugun OT (2021)
    Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
    Acta Oncol, 60 (12), 1565-1571
    DOI 10.1080/0284186X.2021.1973092, PubMed 34486915
43. Yi D, Grøvik E, Tong E, Iv M, Emblem KE, Nilsen LB, Saxhaug C, Latysheva A, Jacobsen KD, Helland Å, Zaharchuk G, Rubin D (2021)
    MRI pulse sequence integration for deep-learning-based brain metastases segmentation
    Med Phys, 48 (10), 6020-6035
    DOI 10.1002/mp.15136, PubMed 34405896
44. Öjlert ÅK, Nebdal D, Snapkov I, Olsen V, Kidman J, Greiff V, Chee J, Helland Å (2021)
    Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor
    Mol Oncol, 15 (11), 2958-2968
    DOI 10.1002/1878-0261.13082, PubMed 34402187
45. Bjaanæs MM, Sande EPS, Loe Ø, Ramberg C, Næss TM, Ottestad A, Rogg LV, Svestad JG, Haakensen VD (2021)
    Improved adaptive radiotherapy to adjust for anatomical alterations during curative treatment for locally advanced lung cancer
    Phys Imaging Radiat Oncol, 18, 51-54
    DOI 10.1016/j.phro.2021.04.003, PubMed 34258408
46. Berg J, Ramberg C, Haugstvedt JOS, Bengtson MB, Gabrielsen AM, Brustugun OT, Halvorsen AR, Helland Å (2021)
    Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
    Front Oncol, 11, 674731
    DOI 10.3389/fonc.2021.674731, PubMed 34109123
47. Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å (2021)
    NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
    J Transl Med, 19 (1), 232
    DOI 10.1186/s12967-021-02905-3, PubMed 34059094
48. Popat S, Brustugun OT, Cadranel J, Felip E, Garassino MC, Griesinger F, Helland Å, Hochmair M, Pérol M, Bent-Ennakhil N, Kruhl C, Novello S (2021)
    Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer
    Lung Cancer, 157, 9-16
    DOI 10.1016/j.lungcan.2021.05.017, PubMed 34051652
49. Slørdahl KS, Klotz D, Olsen JÅ, Skovlund E, Undseth C, Abildgaard HL, Brændengen M, Nesbakken A, Larsen SG, Hanekamp BA, Holmboe L, Tvedt R, Sveen A, Lothe RA, Malinen E, Kaasa S, Guren MG (2021)
    Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer
    Acta Oncol, 60 (7), 921-930
    DOI 10.1080/0284186X.2021.1918763, PubMed 33966592
50. Johannesen TB, Smeland S, Aaserud S, Buanes EA, Skog A, Ursin G, Helland Å (2021)
    COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway
    Front Oncol, 11, 652535
    DOI 10.3389/fonc.2021.652535, PubMed 33842366
51. Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA, Moeller DS, Nyman J, Drugge N, Bergström P, Olofsson J, Rogg LV, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB, Lödén B, Rosenbrand HO, Engelholm S, Haraldsson A, Billiet C, Lewensohn R (2021)
    The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy
    J Thorac Oncol, 16 (7), 1200-1210
    DOI 10.1016/j.jtho.2021.03.019, PubMed 33823286
52. Johnson ML, Zvirbule Z, Laktionov K, Helland A, Cho BC, Gutierrez V, Colinet B, Lena H, Wolf M, Gottfried M, Okamoto I, van der Leest C, Rich P, Hung JY, Appenzeller C, Sun Z, Maag D, Luo Y, Nickner C, Vajikova A, Komarnitsky P, Bar J (2021)
    Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
    J Thorac Oncol, 16 (9), 1570-1581
    DOI 10.1016/j.jtho.2021.03.012, PubMed 33823285
53. Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO (2021)
    High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
    Lancet Oncol, 22 (3), 321-331
    DOI 10.1016/S1470-2045(20)30742-7, PubMed 33662285
54. Brustugun OT, Heggelund L (2021)
    [COVID-19 vaccination of cancer patients]
    Tidsskr Nor Laegeforen, 141 (3)
    DOI 10.4045/tidsskr.21.0026, PubMed 33624982
55. Grøvik E, Yi D, Iv M, Tong E, Nilsen LB, Latysheva A, Saxhaug C, Jacobsen KD, Helland Å, Emblem KE, Rubin DL, Zaharchuk G (2021)
    Handling missing MRI sequences in deep learning segmentation of brain metastases: a multicenter study
    NPJ Digit Med, 4 (1), 33
    DOI 10.1038/s41746-021-00398-4, PubMed 33619361
56. Brustugun OT (2021)
    Cancer and coronavirus risk
    Tidsskr Nor Laegeforen, 141 (2)
    DOI 10.4045/tidsskr.20.1044, PubMed 33528129
57. Öjlert ÅK, Nebdal D, Lund-Iversen M, Åstrøm Ellefsen R, Brustugun OT, Gran JM, Halvorsen AR, Helland Å (2020)
    Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy
    Acta Oncol, 60 (2), 149-156
    DOI 10.1080/0284186X.2020.1854851, PubMed 33356733
58. Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å (2020)
    Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
    Front Oncol, 10, 590755
    DOI 10.3389/fonc.2020.590755, PubMed 33324562
59. Digernes I, Nilsen LB, Grøvik E, Bjørnerud A, Løvland G, Vik-Mo E, Meling TR, Saxhaug C, Helland Å, Jacobsen KD, Geier O, Emblem KE (2020)
    Noise dependency in vascular parameters from combined gradient-echo and spin-echo DSC MRI
    Phys Med Biol, 65 (22), 225020
    DOI 10.1088/1361-6560/abb71a, PubMed 33200748
60. Koch M, Hjermstad MJ, Tomaszewski K, Tomaszewska I, Hornslien K, Harle A, Arraras J, Morag O, Pompili C, Ioannidis G, Navarra C, Chie W, Johnson C, Bohrer T, Janssens A, Kulis D, Bottomley A, Schulz C, Zeman F, Koller M (2020)
    Gender effects on quality of life and symptom burden in patients with lung cancer: results from a prospective, cross-cultural, multi-center study
    J Thorac Dis, 12 (8), 4253-4261
    DOI 10.21037/jtd-20-1054, PubMed 32944337
61. Nilsen LB, Digernes I, Grøvik E, Saxhaug C, Latysheva A, Geier O, Breivik B, Sætre DO, Jacobsen KD, Helland Å, Emblem KE (2020)
    Responses in the diffusivity and vascular function of the irradiated normal brain are seen up until 18 months following SRS of brain metastases
    Neurooncol Adv, 2 (1), vdaa028
    DOI 10.1093/noajnl/vdaa028, PubMed 32642687
62. Halvorsen TO, Stokke K, Killingberg KT, Raj SX, Sørhaug S, Brustugun OT, Fløtten Ø, Helbekkmo N, Hornslien K, Madebo T, Fluge S, Grønberg BH (2020)
    Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
    Acta Oncol, 59 (9), 1051-1057
    DOI 10.1080/0284186X.2020.1778179, PubMed 32543258
63. Haakensen VD, Khadse A, Sandhu V, Halvorsen AR, Solberg SK, Jørgensen LH, Brustugun OT, Kure EH, Helland Å (2020)
    Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
    Int J Cancer, 147 (10), 2957-2966
    DOI 10.1002/ijc.33121, PubMed 32468587
64. Stankovic B, Aamodt H, Bjørhovde HAK, Müller E, Hammarström C, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2020)
    The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
    Scand J Immunol, 92 (2), e12893
    DOI 10.1111/sji.12893, PubMed 32433774
65. Frafjord A, Skarshaug R, Hammarström C, Stankovic B, Dorg LT, Aamodt H, Woldbaek PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2020)
    Antibody combinations for optimized staining of macrophages in human lung tumours
    Scand J Immunol, 92 (1), e12889
    DOI 10.1111/sji.12889, PubMed 32299134
66. Koller M, Shamieh O, Hjermstad MJ, Hornslien K, Young T, Chalk T, Ioannidis G, Harle A, Johnson CD, Tomaszewski KA, Serpentini S, Pinto M, van der Weijst L, Janssens A, Morag O, Chie WC, Arraras JI, Pompili C, Jungraithmayr W, Hechtner M, Katsochi D, Müller K, Gräfenstein L, Schulz C, Bottomley A et al. (2020)
    Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study
    Lancet Oncol, 21 (5), 723-732
    DOI 10.1016/S1470-2045(20)30093-0, PubMed 32213338
67. Eide IJZ, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Brustugun OT (2020)
    Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
    Lung Cancer, 143, 27-35
    DOI 10.1016/j.lungcan.2020.03.009, PubMed 32200138
68. Abravan A, Eide HA, Helland Å, Malinen E (2020)
    Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
    Clin Transl Radiat Oncol, 22, 15-21
    DOI 10.1016/j.ctro.2020.02.005, PubMed 32181373
69. Umu SU, Langseth H, Keller A, Meese E, Helland Å, Lyle R, Rounge TB (2020)
    A 10-year prediagnostic follow-up study shows that serum RNA signals are highly dynamic in lung carcinogenesis
    Mol Oncol, 14 (2), 235-247
    DOI 10.1002/1878-0261.12620, PubMed 31851411
70. Nygård S, Lingjærde OC, Caldas C, Hovig E, Børresen-Dale AL, Helland Å, Haakensen VD (2019)
    PathTracer: High-sensitivity detection of differential pathway activity in tumours
    Sci Rep, 9 (1), 16332
    DOI 10.1038/s41598-019-52529-3, PubMed 31704995
71. Solberg S, Nilssen Y, Brustugun OT, Grimsrud TK, Haram PM, Helbekkmo N, Helland Å, Hjelde HH, Jakobsen B, Møller B, Petersen M, Strand TE, Wahl SGF, Aanerud M, Fjellbirkeland L (2019)
    Increase in curative treatment and survival of lung cancer in Norway 2001-2016
    Eur J Epidemiol, 34 (10), 951-955
    DOI 10.1007/s10654-019-00536-z, PubMed 31313073
72. Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2019)
    Immune Cell Composition in Human Non-small Cell Lung Cancer
    Front Immunol, 9, 3101
    DOI 10.3389/fimmu.2018.03101, PubMed 30774636
73. Shao B, Bjaanæs MM, Helland Å, Schütte C, Conrad T (2019)
    EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
    PLoS One, 14 (1), e0204186
    DOI 10.1371/journal.pone.0204186, PubMed 30703089
74. Bergholtz H, Lien TG, Ursin G, Holmen MM, Helland Å, Sørlie T, Haakensen VD (2019)
    A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue
    J Mammary Gland Biol Neoplasia, 24 (2), 163-175
    DOI 10.1007/s10911-018-09423-x, PubMed 30613869
75. Digernes I, Grøvik E, Nilsen LB, Saxhaug C, Geier O, Reitan E, Sætre DO, Breivik B, Reese T, Jacobsen KD, Helland Å, Emblem KE (2018)
    Brain metastases with poor vascular function are susceptible to pseudoprogression after stereotactic radiation surgery
    Adv Radiat Oncol, 3 (4), 559-567
    DOI 10.1016/j.adro.2018.05.005, PubMed 30370356
76. Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L (2018)
    Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
    J Thorac Oncol, 13 (12), 1906-1918
    DOI 10.1016/j.jtho.2018.08.2027, PubMed 30217492
77. Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Børresen-Dale AL, Helland Å, Markowetz F, Russnes HG (2018)
    Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors
    Mol Oncol, 12 (11), 1838-1855
    DOI 10.1002/1878-0261.12375, PubMed 30133130
78. Brustugun OT, Grønberg BH, Fjellbirkeland L, Helbekkmo N, Aanerud M, Grimsrud TK, Helland Å, Møller B, Nilssen Y, Strand TE, Solberg SK (2018)
    Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
    Lung Cancer, 122, 138-145
    DOI 10.1016/j.lungcan.2018.06.003, PubMed 30032822
79. Abravan A, Eide HA, Løndalen AM, Helland Å, Malinen E (2019)
    Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer
    Mol Imaging Biol, 21 (2), 391-398
    DOI 10.1007/s11307-018-1226-7, PubMed 29916117
80. Eide HA, Knudtsen IS, Sandhu V, Løndalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland Å (2018)
    Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
    Adv Radiat Oncol, 3 (2), 130-138
    DOI 10.1016/j.adro.2017.12.007, PubMed 29904737
81. Hjelle LV, Gundersen POM, Hellesnes R, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Bremnes RM, Haugnes HS (2018)
    Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors
    Acta Oncol, 57 (10), 1392-1400
    DOI 10.1080/0284186X.2018.1473641, PubMed 29775128
82. Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, Helland Å (2018)
    Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
    Acta Oncol, 57 (9), 1225-1231
    DOI 10.1080/0284186X.2018.1465585, PubMed 29683761
83. George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM et al. (2018)
    Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
    Nat Commun, 9 (1), 1048
    DOI 10.1038/s41467-018-03099-x, PubMed 29535388
84. Koller M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, Hornslien K, Harle A, Arraras JI, Morag O, Pompili C, Ioannidis G, Georgiou M, Navarra C, Chie WC, Johnson CD, Himpel A, Schulz C, Bohrer T, Janssens A, Kuliś D, Bottomley A (2017)
    An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients
    Ann Oncol, 28 (11), 2874-2881
    DOI 10.1093/annonc/mdx453, PubMed 28945875
85. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM, Zhang P, Mookerjee B, Johnson BE (2017)
    Dabrafenib plus trametinib in patients with previously untreated BRAF^V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
    Lancet Oncol, 18 (10), 1307-1316
    DOI 10.1016/S1470-2045(17)30679-4, PubMed 28919011
86. Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG (2017)
    Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
    Oncotarget, 8 (34), 57121-57133
    DOI 10.18632/oncotarget.19078, PubMed 28915659
87. Vandraas KF, Torfoss D, Berstad AE, Horndalsveen H, Turowski G (2017)
    [Cancer patient in his 50's with troublesome palpitations]
    Tidsskr Nor Laegeforen, 137 (16)
    DOI 10.4045/tidsskr.17.0204, PubMed 28871750
88. Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA (2017)
    High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival
    Int J Cancer, 141 (1), 184-190
    DOI 10.1002/ijc.30726, PubMed 28387924
89. Halvorsen AR, Kristensen G, Embleton A, Adusei C, Barretina-Ginesta MP, Beale P, Helland Å (2017)
    Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
    Dis Markers, 2017, 3098542
    DOI 10.1155/2017/3098542, PubMed 28293063
90. Halvorsen AR, Helland Å, Gromov P, Wielenga VT, Talman MM, Brunner N, Sandhu V, Børresen-Dale AL, Gromova I, Haakensen VD (2016)
    Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer
    Mol Oncol, 11 (2), 220-234
    DOI 10.1002/1878-0261.12025, PubMed 28145100
91. Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, Møller Talman ML, Brunner N, Børresen-Dale AL, Gromov P, Helland Å, Kristensen VN, Gromova I (2016)
    Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics
    Oncoimmunology, 5 (12), e1248015
    DOI 10.1080/2162402X.2016.1248015, PubMed 28123884
92. McGowan M, Hoven AS, Lund-Iversen M, Solberg S, Helland Å, Hirsch FR, Brustugun OT (2016)
    PIK3CA mutations as prognostic factor in squamous cell lung carcinoma
    Lung Cancer, 103, 52-57
    DOI 10.1016/j.lungcan.2016.11.018, PubMed 28024696
93. Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
    Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
    Clin Transl Immunology, 5 (11), e109
    DOI 10.1038/cti.2016.65, PubMed 27990285
94. Halvorsen TO, Herje M, Levin N, Bremnes RM, Brustugun OT, Fløtten Ø, Kaasa S, Sundstrøm S, Grønberg BH (2016)
    Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer
    Lung Cancer, 102, 9-14
    DOI 10.1016/j.lungcan.2016.10.003, PubMed 27987595
95. Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN (2017)
    DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
    Oncotarget, 8 (1), 1074-1082
    DOI 10.18632/oncotarget.13718, PubMed 27911866
96. Brustugun OT, Sprauten M, Helland Å (2016)
    Real-world data on nivolumab treatment of non-small cell lung cancer
    Acta Oncol, 56 (3), 438-440
    DOI 10.1080/0284186X.2016.1253865, PubMed 27892773
97. Weischenfeldt J, Dubash T, Drainas AP, Mardin BR, Chen Y, Stütz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Erkek S, Siegl C, Brenner H, Brustugun OT, Dieter SM, Northcott PA, Petersen I, Pfister SM, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R et al. (2016)
    Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
    Nat Genet, 49 (1), 65-74
    DOI 10.1038/ng.3722, PubMed 27869826
98. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC et al. (2016)
    The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
    J Thorac Oncol, 12 (2), 194-207
    DOI 10.1016/j.jtho.2016.10.003, PubMed 27729297
99. Nyman J, Hallqvist A, Lund JÅ, Brustugun OT, Bergman B, Bergström P, Friesland S, Lewensohn R, Holmberg E, Lax I (2016)
    SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC
    Radiother Oncol, 121 (1), 1-8
    DOI 10.1016/j.radonc.2016.08.015, PubMed 27600155
100. Halvorsen TO, Sundstrøm S, Fløtten Ø, Brustugun OT, Brunsvig P, Aasebø U, Bremnes RM, Kaasa S, Grønberg BH (2016)
     Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer
     Acta Oncol, 55 (11), 1349-1354
     DOI 10.1080/0284186X.2016.1201216, PubMed 27549509
101. Hjelle LV, Bremnes RM, Gundersen POM, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Haugnes HS (2016)
     Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors
     Urol Oncol, 34 (11), 487.e13-487.e20
     DOI 10.1016/j.urolonc.2016.06.012, PubMed 27523611
102. Rud AK, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM (2016)
     Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
     Diagn Pathol, 11 (1), 50
     DOI 10.1186/s13000-016-0504-4, PubMed 27316334
103. Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
     TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
     Front Genet, 7, 85
     DOI 10.3389/fgene.2016.00085, PubMed 27242894
104. Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC, López-Guerrero JA, Brustugun OT, Helland Å (2016)
     A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
     Oncotarget, 7 (24), 37250-37259
     DOI 10.18632/oncotarget.9363, PubMed 27191990
105. Varghese M, Nymoen HG, Saxhaug C, Krossnes B, Abdol Mohieb Hosainey S, Meling TR, Brandal P (2016)
     Symptomatic spinal metastasis from intracranial glioblastoma multiforme - Two illustrative cases and a review of the literature
     Acta Oncol, 55 (9-10), 1236-1238
     DOI 10.3109/0284186X.2016.1161824, PubMed 27174685
106. Haakensen VD, Nygaard V, Greger L, Aure MR, Fromm B, Bukholm IR, Lüders T, Chin SF, Git A, Caldas C, Kristensen VN, Brazma A, Børresen-Dale AL, Hovig E, Helland Å (2016)
     Subtype-specific micro-RNA expression signatures in breast cancer progression
     Int J Cancer, 139 (5), 1117-28
     DOI 10.1002/ijc.30142, PubMed 27082076
107. Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2016)
     Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
     F1000Res, 5, 38
     DOI 10.12688/f1000research.7599.1, PubMed 27081474
108. Eide HA, Halvorsen AR, Bjaanæs MM, Piri H, Holm R, Solberg S, Jørgensen L, Brustugun OT, Kiserud CE, Helland Å (2016)
     The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes
     BMC Cancer, 16, 71
     DOI 10.1186/s12885-016-2104-9, PubMed 26858029
109. Bjaanæs MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, Jørgensen L, Kure E, Edvardsen H, Børresen-Dale AL, Brustugun OT, Tost J, Kristensen V, Helland Å (2015)
     Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
     Mol Oncol, 10 (2), 330-43
     DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720
110. Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SG, Helgeland L, Fløtten O, Pohl M, Al-Shibli K, Sandanger TM, Pezzella F, Busund LT, Bremnes RM (2015)
     Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer
     Ann Oncol, 27 (2), 225-32
     DOI 10.1093/annonc/mdv560, PubMed 26578726
111. Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen ED, Sundstrøm S, Norwegian Lung Cancer Study Group (2015)
     Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
     Acta Oncol, 55 (5), 591-7
     DOI 10.3109/0284186X.2015.1092584, PubMed 26494411
112. Nilssen Y, Strand TE, Fjellbirkeland L, Bartnes K, Brustugun OT, O'Connell DL, Yu XQ, Møller B (2015)
     Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage
     Int J Cancer, 138 (6), 1350-60
     DOI 10.1002/ijc.29875, PubMed 26421593
113. Lund-Iversen M, Grøholt KK, Helland Å, Borgen E, Brustugun OT (2015)
     NUT expression in primary lung tumours
     Diagn Pathol, 10, 156
     DOI 10.1186/s13000-015-0395-9, PubMed 26341600
114. Arnesen MR, Knudtsen IS, Rekstad BL, Eilertsen K, Dale E, Bruheim K, Helland Å, Løndalen AM, Hellebust TP, Malinen E (2015)
     Dose painting by numbers in a standard treatment planning system using inverted dose prescription maps
     Acta Oncol, 54 (9), 1607-13
     DOI 10.3109/0284186X.2015.1061690, PubMed 26213311
115. George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N et al. (2015)
     Comprehensive genomic profiles of small cell lung cancer
     Nature, 524 (7563), 47-53
     DOI 10.1038/nature14664, PubMed 26168399
116. Darabi H, McCue K, Beesley J, Michailidou K, Nord S, Kar S, Humphreys K, Thompson D, Ghoussaini M, Bolla MK, Dennis J, Wang Q, Canisius S, Scott CG, Apicella C, Hopper JL, Southey MC, Stone J, Broeks A, Schmidt MK, Scott RJ, Lophatananon A, Muir K, Beckmann MW, Ekici AB et al. (2015)
     Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
     Am J Hum Genet, 97 (1), 22-34
     DOI 10.1016/j.ajhg.2015.05.002, PubMed 26073781
117. Witek B, El Wakil A, Nord C, Ahlgren U, Eriksson M, Vernersson-Lindahl E, Helland Å, Alexeyev OA, Hallberg B, Palmer RH (2015)
     Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism
     PLoS One, 10 (5), e0123542
     DOI 10.1371/journal.pone.0123542, PubMed 25955180
118. Syljuåsen RG, Hasvold G, Hauge S, Helland Å (2015)
     Targeting lung cancer through inhibition of checkpoint kinases
     Front Genet, 6, 70
     DOI 10.3389/fgene.2015.00070, PubMed 25774168
119. Brustugun OT (2014)
     Hypoxia as a cause of treatment failure in non-small cell carcinoma of the lung
     Semin Radiat Oncol, 25 (2), 87-92
     DOI 10.1016/j.semradonc.2014.11.006, PubMed 25771412
120. Brustugun OT (2015)
     [Re: In momentous development?]
     Tidsskr Nor Laegeforen, 135 (5), 413-4
     DOI 10.4045/tidsskr.15.0208, PubMed 25761018
121. Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli K, Kiselev Y, Sandanger TM, Andersen S, Pezzella F, Bremnes RM, Busund LT (2015)
     Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
     Clin Cancer Res, 21 (11), 2635-43
     DOI 10.1158/1078-0432.CCR-14-1905, PubMed 25680376
122. Potapenko IO, Lüders T, Russnes HG, Helland Å, Sørlie T, Kristensen VN, Nord S, Lingjærde OC, Børresen-Dale AL, Haakensen VD (2015)
     Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
     Mol Oncol, 9 (4), 861-76
     DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580
123. Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015)
     Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
     Genome Biol, 16 (1), 7
     DOI 10.1186/s13059-014-0558-0, PubMed 25650807
124. Trinh A, Rye IH, Almendro V, Helland A, Russnes HG, Markowetz F (2014)
     GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images
     Genome Biol, 15 (8), 442
     DOI 10.1186/s13059-014-0442-y, PubMed 25168174
125. Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg F, Naume B, Helland A, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
     Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
     Genome Biol, 15 (8), 435
     DOI 10.1186/PREACCEPT-2333349012841587, PubMed 25146004
126. Brustugun OT, Møller B, Helland A (2014)
     Years of life lost as a measure of cancer burden on a national level
     Br J Cancer, 111 (5), 1014-20
     DOI 10.1038/bjc.2014.364, PubMed 24983370
127. Mynarek G, Aaløkken TM, Martinsen AC, Brustugun OT (2014)
     [Re: Limited malignancy screening of patients with idiopathic venous thromboembolism]
     Tidsskr Nor Laegeforen, 134 (8), 814-5
     DOI 10.4045/tidsskr.14.0468, PubMed 24780975
128. Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidal D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M et al. (2014)
     Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
     Nat Commun, 5, 3518
     DOI 10.1038/ncomms4518, PubMed 24670920
129. Saldova R, Asadi Shehni A, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, Helland A, Yakhini Z, Børresen-Dale AL, Rudd PM (2014)
     Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC
     J Proteome Res, 13 (5), 2314-27
     DOI 10.1021/pr401092y, PubMed 24669823
130. Halvorsen AR, Helland A, Fleischer T, Haug KM, Grenaker Alnaes GI, Nebdal D, Syljuåsen RG, Touleimat N, Busato F, Tost J, Saetersdal AB, Børresen-Dale AL, Kristensen V, Edvardsen H (2014)
     Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy
     Int J Cancer, 135 (9), 2085-95
     DOI 10.1002/ijc.28862, PubMed 24658971
131. Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, Helland A (2014)
     Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
     Int J Cancer, 135 (8), 1812-21
     DOI 10.1002/ijc.28828, PubMed 24599520
132. Brustugun OT, Khattak AM, Trømborg AK, Beigi M, Beiske K, Lund-Iversen M, Helland Å (2014)
     BRAF-mutations in non-small cell lung cancer
     Lung Cancer, 84 (1), 36-8
     DOI 10.1016/j.lungcan.2014.01.023, PubMed 24552757
133. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K (2014)
     Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity
     Cell Rep, 6 (3), 514-27
     DOI 10.1016/j.celrep.2013.12.041, PubMed 24462293
134. Grønberg BH, Lund-Iversen M, Strøm EH, Brustugun OT, Scott H (2013)
     Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy
     J Thorac Oncol, 8 (10), 1255-64
     DOI 10.1097/JTO.0b013e3182a406a3, PubMed 24457236
135. Sagerup CM, Nymoen DA, Halvorsen AR, Lund-Iversen M, Helland A, Brustugun OT (2014)
     Human papilloma virus detection and typing in 334 lung cancer patients
     Acta Oncol, 53 (7), 952-7
     DOI 10.3109/0284186X.2013.879608, PubMed 24446743
136. Sprauten M, Brydøy M, Haugnes HS, Cvancarova M, Bjøro T, Bjerner J, Fosså SD, Oldenburg J (2014)
     Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors
     J Clin Oncol, 32 (6), 571-8
     DOI 10.1200/JCO.2013.51.2715, PubMed 24419125
137. Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM (2013)
     Osteopontin is a prognostic biomarker in non-small cell lung cancer
     BMC Cancer, 13, 540
     DOI 10.1186/1471-2407-13-540, PubMed 24215488
138. Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
     Clinical significance of disseminated tumour cells in non-small cell lung cancer
     Br J Cancer, 109 (5), 1264-70
     DOI 10.1038/bjc.2013.450, PubMed 23942067
139. Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, Kaspi A, Hu R, Robens J, Nikolskaya T, Haakensen VD, Schnitt SJ, Argani P, Ethington G, Panos L, Grant M et al. (2013)
     Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics
     Cell Stem Cell, 13 (1), 117-30
     DOI 10.1016/j.stem.2013.05.004, PubMed 23770079
140. Nordgård O, Singh G, Solberg S, Jørgensen L, Halvorsen AR, Smaaland R, Brustugun OT, Helland Å (2013)
     Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer
     PLoS One, 8 (5), e62153
     DOI 10.1371/journal.pone.0062153, PubMed 23671585
141. Brustugun OT, Helland Å (2013)
     Rapid reduction in the incidence of cancer of unknown primary. A population-based study
     Acta Oncol, 53 (1), 134-7
     DOI 10.3109/0284186X.2013.783230, PubMed 23550957
142. Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL (2013)
     High levels of genomic aberrations in serous ovarian cancers are associated with better survival
     PLoS One, 8 (1), e54356
     DOI 10.1371/journal.pone.0054356, PubMed 23372714
143. Riis ML, Lüders T, Markert EK, Haakensen VD, Nesbakken AJ, Kristensen VN, Bukholm IR (2012)
     Molecular profiles of pre- and postoperative breast cancer tumours reveal differentially expressed genes
     ISRN Oncol, 2012, 450267
     DOI 10.5402/2012/450267, PubMed 23227362
144. Helland Å, Solberg S, Brustugun OT (2012)
     Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases
     J Thorac Oncol, 7 (12), 1858-1861
     DOI 10.1097/JTO.0b013e318275b346, PubMed 23154557
145. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I et al. (2012)
     Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
     Nat Genet, 44 (10), 1104-10
     DOI 10.1038/ng.2396, PubMed 22941188
146. Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland Å, Brustugun OT (2012)
     Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations
     J Thorac Oncol, 7 (9), 1471-3
     DOI 10.1097/JTO.0b013e3182614a9d, PubMed 22895145
147. Rud AK, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Mælandsmo GM, Boye K (2012)
     Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
     BMC Cancer, 12, 333
     DOI 10.1186/1471-2407-12-333, PubMed 22853000
148. Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C (2012)
     Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
     Br J Cancer, 107 (3), 442-7
     DOI 10.1038/bjc.2012.284, PubMed 22759880
149. Brustugun OT, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, Scott H, Dønnem T, Bremnes R, Berg T, Grønberg BH, Dai HY, Wahl SG, Mangseth K, Helgeland L (2012)
     [Mutation testing for non-small-cell lung cancer]
     Tidsskr Nor Laegeforen, 132 (8), 952-5
     DOI 10.4045/tidsskr.11.1017, PubMed 22562326
150. Nordlund MS, Stieber P, Brustugun OT, Warren DJ, Paus E (2012)
     Characteristics and clinical validity of two immunoassays for ProGRP
     Tumour Biol, 33 (4), 1105-13
     DOI 10.1007/s13277-012-0351-1, PubMed 22399443
151. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F et al. (2011)
     Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer
     Cancer Discov, 1 (1), 78-89
     DOI 10.1158/2159-8274.CD-11-0005, PubMed 22328973
152. Waldeland E, Ramberg C, Arnesen MR, Helland A, Brustugun OT, Malinen E (2012)
     Dosimetric impact of a frame-based strategy in stereotactic radiotherapy of lung tumors
     Acta Oncol, 51 (5), 603-9
     DOI 10.3109/0284186X.2012.658115, PubMed 22304490
153. Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, Beard C, Haugnes HS, Fosså SD, Oldenburg J, Travis LB (2011)
     Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer
     J Clin Oncol, 30 (3), 300-7
     DOI 10.1200/JCO.2011.37.4025, PubMed 22184390
154. Haakensen VD, Lingjaerde OC, Lüders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Børresen-Dale AL, Helland A (2011)
     Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features
     BMC Med Genomics, 4, 77
     DOI 10.1186/1755-8794-4-77, PubMed 22044755
155. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL (2011)
     Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
     Proc Natl Acad Sci U S A, 109 (8), 2802-7
     DOI 10.1073/pnas.1108781108, PubMed 21908711
156. Sagerup CM, Småstuen M, Johannesen TB, Helland A, Brustugun OT (2012)
     Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients
     J Thorac Oncol, 7 (1), 57-63
     DOI 10.1097/JTO.0b013e3182307f7e, PubMed 21900838
157. Haakensen VD, Bjøro T, Lüders T, Riis M, Bukholm IK, Kristensen VN, Troester MA, Homen MM, Ursin G, Børresen-Dale AL, Helland Å (2011)
     Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas
     BMC Cancer, 11, 332
     DOI 10.1186/1471-2407-11-332, PubMed 21812955
158. Knudtsen IS, Rødal J, Brustugun OT, Helland Å, Skretting A, Malinen E (2011)
     Dynamic respiratory gated (18)FDG-PET of lung tumors - a feasibility study
     Acta Oncol, 50 (6), 889-96
     DOI 10.3109/0284186X.2011.583266, PubMed 21767189
159. Berg A, Brustugun OT, Lund-Iversen M, Helland Å (2011)
     Palmar bullous blistering induced by erlotinib
     J Thorac Oncol, 6 (5), 954
     DOI 10.1097/JTO.0b013e318211136b, PubMed 21623268
160. Helland Å, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jørgensen L, Ariansen S, Brustugun OT (2011)
     EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery
     J Thorac Oncol, 6 (5), 947-50
     DOI 10.1097/JTO.0b013e31820db209, PubMed 21623266
161. Turzer M, Brustugun OT, Waldeland E, Helland A (2011)
     Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidity
     Case Rep Oncol, 4 (1), 25-34
     DOI 10.1159/000324113, PubMed 21526003
162. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I et al. (2010)
     Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer
     Sci Transl Med, 2 (62), 62ra93
     DOI 10.1126/scitranslmed.3001451, PubMed 21160078
163. Haakensen VD, Biong M, Lingjærde OC, Holmen MM, Frantzen JO, Chen Y, Navjord D, Romundstad L, Lüders T, Bukholm IK, Solvang HK, Kristensen VN, Ursin G, Børresen-Dale AL, Helland A (2010)
     Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density
     Breast Cancer Res, 12 (4), R65
     DOI 10.1186/bcr2632, PubMed 20799965
164. Turzer M, Brustugun OT, Helland A (2010)
     Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
     Case Rep Oncol, 3 (2), 195-201
     DOI 10.1159/000317104, PubMed 20740196
165. Strand TE, Brunsvig PF, Johannessen DC, Sundstrøm S, Wang M, Hornslien K, Bremnes RM, Stensvold A, Garpestad O, Norstein J (2010)
     Potentially curative radiotherapy for non-small-cell lung cancer in Norway: a population-based study of survival
     Int J Radiat Oncol Biol Phys, 80 (1), 133-41
     DOI 10.1016/j.ijrobp.2010.01.050, PubMed 20452137
166. Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, Vice C, Brustugun OT, Denko NC, Koong AC, Giaccia A, Le QT (2010)
     The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways
     PLoS One, 5 (3), e9633
     DOI 10.1371/journal.pone.0009633, PubMed 20224789
167. Marienhagen K, Helland A, Nordberg T, Guren MG, Hofsli E (2010)
     [How do Norwegian oncologists perceive their working conditions?]
     Tidsskr Nor Laegeforen, 130 (5), 487-9
     DOI 10.4045/tidsskr.08.0305, PubMed 20224615
168. Rogg L, Aasland OG, Graugaard PK, Loge JH (2010)
     Direct communication, the unquestionable ideal? Oncologists' accounts of communication of bleak prognoses
     Psychooncology, 19 (11), 1221-8
     DOI 10.1002/pon.1691, PubMed 20186873
169. Potapenko IO, Haakensen VD, Lüders T, Helland A, Bukholm I, Sørlie T, Kristensen VN, Lingjaerde OC, Børresen-Dale AL (2009)
     Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression
     Mol Oncol, 4 (2), 98-118
     DOI 10.1016/j.molonc.2009.12.001, PubMed 20060370
170. Sagerup CM, Brustugun OT, Jørgensen L (2009)
     [A 67-year old man with right arm paresthesias]
     Tidsskr Nor Laegeforen, 129 (24), 2613-5
     DOI 10.4045/tidsskr.09.0319, PubMed 20029558
171. Helland A, Brustugun OT (2009)
     [Lung cancer in smokers and never-smokers]
     Tidsskr Nor Laegeforen, 129 (18), 1859-62
     DOI 10.4045/tidsskr.08.0652, PubMed 19844277
172. Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, Ciotti M, Das BR, Del Mistro A, Dybikowska A, Giuliano AR, Gudleviciene Z, Gyllensten U, Haws AL, Helland A, Herrington CS, Hildesheim A, Humbey O, Jee SH, Kim JW, Madeleine MM, Menczer J, Ngan HY, Nishikawa A, Niwa Y et al. (2009)
     TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies
     Lancet Oncol, 10 (8), 772-84
     DOI 10.1016/S1470-2045(09)70187-1, PubMed 19625214
173. Kamalakaran S, Kendall J, Zhao X, Tang C, Khan S, Ravi K, Auletta T, Riggs M, Wang Y, Helland A, Naume B, Dimitrova N, Børresen-Dale AL, Hicks J, Lucito R (2009)
     Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation
     Nucleic Acids Res, 37 (12), e89
     DOI 10.1093/nar/gkp413, PubMed 19474344
174. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB (2009)
     Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis
     PLoS One, 4 (5), e5583
     DOI 10.1371/journal.pone.0005583, PubMed 19440550
175. Rogg L, Loge JH, Aasland OG, Graugaard PK (2009)
     Physicians' attitudes towards disclosure of prognostic information: a survey among a representative cross-section of 1605 Norwegian physicians
     Patient Educ Couns, 77 (2), 242-7
     DOI 10.1016/j.pec.2009.03.007, PubMed 19356882
176. Sande TA, Ruenes R, Lund JA, Bruland OS, Hornslien K, Bremnes R, Kaasa S (2009)
     Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: results from a randomised multicentre trial
     Radiother Oncol, 91 (2), 261-6
     DOI 10.1016/j.radonc.2009.02.014, PubMed 19307034
177. Aavitsland P, Helland A (2008)
     [The selected contagions]
     Tidsskr Nor Laegeforen, 128 (20), 2304
     PubMed 19096483
178. Lyng H, Lando M, Brøvig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, Stokke T (2008)
     GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
     Genome Biol, 9 (5), R86
     DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990
179. Fredriksson S, Horecka J, Brustugun OT, Schlingemann J, Koong AC, Tibshirani R, Davis RW (2008)
     Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer
     Clin Chem, 54 (3), 582-9
     DOI 10.1373/clinchem.2007.093195, PubMed 18171715
180. Thorsen L, Dahl AA, Skovlund E, Hornslien K, Fosså SD (2007)
     Effectiveness after 1 year of a short-term physical activity intervention on cardiorespiratory fitness in cancer patients
     J Clin Oncol, 25 (10), 1301-2
     DOI 10.1200/JCO.2007.10.6682, PubMed 17401029
181. Edvardsen H, Kristensen VN, Grenaker Alnaes GI, Bøhn M, Erikstein B, Helland A, Børresen-Dale AL, Fosså SD (2007)
     Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy
     Int J Radiat Oncol Biol Phys, 67 (4), 1163-71
     DOI 10.1016/j.ijrobp.2006.11.009, PubMed 17336217
182. Rogg L, Graugaard PK, Loge JH (2006)
     Physicians' interpretation of the prognostic term "terminal": a survey among Norwegian physicians
     Palliat Support Care, 4 (3), 273-8
     DOI 10.1017/s1478951506060342, PubMed 17066968
183. Thorsen L, Nystad W, Stigum H, Hjermstad M, Oldervoll L, Martinsen EW, Hornslien K, Strømme SB, Dahl AA, Fosså SD (2006)
     Cardiorespiratory fitness in relation to self-reported physical function in cancer patients after chemotherapy
     J Sports Med Phys Fitness, 46 (1), 122-7
     PubMed 16596110
184. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006)
     Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
     PLoS Med, 3 (3), e47
     DOI 10.1371/journal.pmed.0030047, PubMed 16417408
185. Gustafsson BI, Thommesen L, Stunes AK, Tommeras K, Westbroek I, Waldum HL, Slørdahl K, Tamburstuen MV, Reseland JE, Syversen U (2006)
     Serotonin and fluoxetine modulate bone cell function in vitro
     J Cell Biochem, 98 (1), 139-51
     DOI 10.1002/jcb.20734, PubMed 16408289
186. Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G (2006)
     Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
     Int J Cancer, 118 (11), 2877-81
     DOI 10.1002/ijc.21709, PubMed 16381016
187. Brustugun OT, Reed W, Poulsen JP, Bruland OS (2005)
     Primary osteosarcoma of the breast
     Acta Oncol, 44 (7), 767-70
     DOI 10.1080/02841860500254897, PubMed 16227171
188. Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R (2005)
     Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
     Am J Clin Pathol, 124 (3), 392-401
     DOI 10.1309/BL7E-MW66-LQX6-GFRP, PubMed 16191507
189. Thorsen L, Skovlund E, Strømme SB, Hornslien K, Dahl AA, Fosså SD (2005)
     Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy
     J Clin Oncol, 23 (10), 2378-88
     DOI 10.1200/JCO.2005.04.106, PubMed 15800330
190. Wang Y, Helland A, Holm R, Kristensen GB, Børresen-Dale AL (2005)
     PIK3CA mutations in advanced ovarian carcinomas
     Hum Mutat, 25 (3), 322
     DOI 10.1002/humu.9316, PubMed 15712344
191. Lyng H, Beigi M, Svendsrud DH, Brustugun OT, Stokke T, Kristensen GB, Sundfør K, Skjønsberg A, De Angelis PM (2004)
     Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix
     Int J Cancer, 111 (3), 358-66
     DOI 10.1002/ijc.20258, PubMed 15221962
192. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A (2004)
     Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
     Hum Mutat, 24 (1), 21-34
     DOI 10.1002/humu.20055, PubMed 15221786
193. Kristiansen M, Helland A, Kristensen GB, Olsen AO, Lønning PE, Børresen-Dale AL, Ørstavik KH (2003)
     X chromosome inactivation in cervical cancer patients
     Cancer Genet Cytogenet, 146 (1), 73-6
     DOI 10.1016/s0165-4608(03)00152-3, PubMed 14499700
194. Tronstad KJ, Gjertsen BT, Krakstad C, Berge K, Brustugun OT, Døskeland SO, Berge RK (2003)
     Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells
     Chem Biol, 10 (7), 609-18
     DOI 10.1016/s1074-5521(03)00142-x, PubMed 12890534
195. Brustugun OT, Nome O, Bruland S ØS, Ottestad L, Lilleby W (2003)
     [Breast cancer patients' assessment of waiting time before radiotherapy]
     Tidsskr Nor Laegeforen, 123 (12), 1685-6
     PubMed 12821991
196. Fladmark KE, Brustugun OT, Mellgren G, Krakstad C, Boe R, Vintermyr OK, Schulman H, Doskeland SO (2001)
     Ca2+/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis
     J Biol Chem, 277 (4), 2804-11
     DOI 10.1074/jbc.M109049200, PubMed 11713251
197. Kleveland O, Syversen U, Slørdahl K, Waldum HL (2001)
     Hypergastrinemia as a cause of chromogranin a increase in blood in patients suspected to have neuroendocrine tumor
     Digestion, 64 (2), 71-4
     DOI 10.1159/000048842, PubMed 11684818
198. Schwede F, Brustugun OT, Zorn-Kruppa M, Døskeland SO, Jastorff B (2000)
     Membrane-permeant, bioactivatable analogues of cGMP as inducers of cell death in IPC-81 leukemia cells
     Bioorg Med Chem Lett, 10 (6), 571-3
     DOI 10.1016/s0960-894x(00)00050-0, PubMed 10741556
199. Fladmark KE, Brustugun OT, Hovland R, Boe R, Gjertsen BT, Zhivotovsky B, Døskeland SO (1999)
     Ultrarapid caspase-3 dependent apoptosis induction by serine/threonine phosphatase inhibitors
     Cell Death Differ, 6 (11), 1099-108
     DOI 10.1038/sj.cdd.4400590, PubMed 10578179
200. Zhivotovsky B, Orrenius S, Brustugun OT, Døskeland SO (1998)
     Injected cytochrome c induces apoptosis
     Nature, 391 (6666), 449-50
     DOI 10.1038/35060, PubMed 9461210
201. Vintermyr OK, Bøe R, Brustugun OT, Maronde E, Aakvaag A, Døskeland SO (1995)
     Cyclic adenosine monophosphate (cAMP) analogs 8-Cl- and 8-NH2-cAMP induce cell death independently of cAMP kinase-mediated inhibition of the G1/S transition in mammary carcinoma cells (MCF-7)
     Endocrinology, 136 (6), 2513-20
     DOI 10.1210/endo.136.6.7750473, PubMed 7750473
202. Bruserud O, Tore Gjertsen B, Brustugun OT, Bassøe CF, Nesthus I, Espen Akselsen P, Bühring HJ, Pawelec G (1995)
     Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia
     Leukemia, 9 (11), 1910-20
     PubMed 7475283
203. Rogg LV (2015)
     Medical humanities companion, vol 4, Prognosis
     Tidsskr. Nor. Laegeforen., 135 (4), 358
     DOI 10.4045/tidsskr.14.1392
204. Helland A (2015)
     Cancer stem cells
     Tidsskr. Nor. Laegeforen., 135 (8), 783
     DOI 10.4045/tidsskr.15.0031
205. Rogg L (2018)
     NO MAN'S LAND For those who did not die, who are no longer sick, nor are they healthy
     Tidsskr. Nor. Laegeforen., 138 (5), 483
206. Farooqi SJ, Helland A, Haakensen VD, Bjaanaes MM (2021)
     Immunotherapy in malignant pleural mesothelioma
     Tidsskr. Nor. Laegeforen., 141 (12), 1167-1169
207. Vandraas KF, Torfoss D, Berstad AE, Horndalsveen H, Turowski G (2017)
     Cancer patient in the 50s with troublesome palpitations
     Tidsskr. Nor. Laegeforen., 137 (16), 1210-1213
208. Brustugun OT, Sorhaug S, Gronberg BH, Aanerud M, Al-Zubayidy MMZ, Fjellbirkeland L, Helland A, Berg J, Andreassen B, Paulsen EE, Haram PM, Ashraf H, Wahl SGF (2020)
     Lung cancer: Improved prognosis presents capacity challenges
     Tidsskr. Nor. Laegeforen., 140 (5), 432-434
209. Helland A (2018)
     Groundbreaking basic research
     Tidsskr. Nor. Laegeforen., 138 (20), 1905
210. Helland A (2015)
     Viruses and human cancer
     Tidsskr. Nor. Laegeforen., 135 (9), 874
     DOI 10.4045/tidsskr.15.0167
211. Helland A (2015)
     Gene jockeys Life science and the rise of biotech enterprise.
     Tidsskr. Nor. Laegeforen., 135 (4), 356
     DOI 10.4045/tidsskr.14.1367
212. Brustugun OT (2016)
     Stratification in advanced non-small cell lung cancer: precision medicine in practice
     Expert Rev. Precis. Med. Drug Dev., 1 (3), 279-287
     DOI 10.1080/23808993.2016.1176861